Question 1

What is AVLAYAH?

Accepted Answer

AVLAYAH is a Other.

Question 2

How often does AVLAYAH appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was AVLAYAH first tracked by Ergen?

Accepted Answer

First tracked on Jun 18, 2026.

Question 4

When was AVLAYAH last mentioned in news?

Accepted Answer

Last active on Jun 18, 2026.

Question 5

What is AVLAYAH's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AVLAYAH in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AVLAYAH?

Accepted Answer

Denali Sells PRV for $195M (Jun 18, 2026, 6 articles).

Question 8

How did the "Denali Sells PRV for $195M" event impact AVLAYAH?

Accepted Answer

AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier, and its approval led to Denali Therapeutics Inc. being awarded the Priority Review Voucher.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.